coposys-dev
[Top][All Lists]
Advanced

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[Coposys-dev] News Report


From: Joan Clarke
Subject: [Coposys-dev] News Report
Date: Tue, 03 Jan 2006 23:19:08 -0500

Date: 4 Jan 2006
Investment Times Alert: (STRONG)
Harbin Pingchuan Pharmaceutical: PGCN
Current Price: $0.47
Shares Outstanding: 20 Million 
Market Capitalization: $6 Million 
Short Term Target: $2.25 
12month Target: $8 

*********INVESTER ALERT ISSUED FOR WEDNESDAY********* 
 
Pingchuan Pharmaceutical Inc. ("PINGCHUAN") is a modernized 
pharmaceutical manufacturer with first-class medical R&D ability, 
pioneered medicine products, and well-established 
marketing network. Since its establishment, PINGCHUAN has focused 
its businesses on diabetes medicine and its medical products. 
The products of PINGCHUAN include health care products, 
varieties of medicine, as well as medical apparatus. 
Kang Da Glycosuria Capsule is a successful product of PINGCHUAN 
for treating diabetes, which was first developed in 1998 
and introduced to the market in 2001. 
PINGCHUAN has well-established marketing network and sale branches, 
which include about 180,000 retail pharmacies/drugstores across China, 
agency network in major cities like Beijing, Shanghai, Guangzhou, and 
Xi'an, special counter sale at drug chain stores in key regions, 
residence community clinic sale and promotion, as well 
as internet marketing through the company's website. 
The marketing network of PINGCHUAN covers more than 
50% districts of China and exports to US, Japan, Russia, 
and south-eastern Asia. 
******************************** 

Remember the gains from our recent "Strong Buy" recommendations... 


It is only a matter of time before it is released out 
into the investment community and they take it to the moon. 

TRADING SYMBOL: PGCN 
Put it on your screen now !!! 
The key to making serious money through investing 
is not to follow the crowd. 

SmallCap-Investors issued this Alert for Jan 4. 
This is a MUST Watch for all Investors.






reply via email to

[Prev in Thread] Current Thread [Next in Thread]